Breakthrough In investigational HIV Vaccine Prevents Infections In 31% Of Cases

A phase III efficacy trial planned by the U.S. Military HIV Research Program and the Thai Ministry of Public Health, involving 16,000 volunteers in Thailand has revealed that volunteers who received a prime-boost mixture of two AIDS vaccine candidates - ALVAC combined with AIDSVAX - had infection rates 31.2% lower than people who received a placebo. The two vaccines have no significant effect on HIV infection rates when used alone, but appear to be surprisingly effective when used together.

The official support of this trial was the U.S. Army Surgeon General via the U.S. Army Medical Materiel Development Activity. ALVAC is made by Sanofi-Aventis, SA, France, while AIDSVAX is made by VaxGen Inc., USA.

AIVI (International AIDS Vaccine Initiative) greeted this news with enthusiasm. IAVI President and CEO Seth Berkley, said "The outcome is very exciting news and a significant scientific achievement. It's the first demonstration that a candidate AIDS vaccine provides benefit in humans. Until now, we've had confirmation of feasibility for an AIDS vaccine in animal models. Now, we've got a vaccine candidate that appears to show a protective effect in humans, albeit partially."

useful links: los angeles movers, transport rankings 

You have read this article Health with the title Breakthrough In investigational HIV Vaccine Prevents Infections In 31% Of Cases. You can bookmark this page URL https://roxpolitix.blogspot.com/2009/09/breakthrough-in-investigational-hiv.html. Thanks!